The Development of Surface-Modified Liposomes as an Intranasal Delivery System for Group A Streptococcus Vaccines

Intranasal vaccine administration can overcome the disadvantages of injectable vaccines and present greater efficiency for mass immunization. However, the development of intranasal vaccines is challenged by poor mucosal immunogenicity of antigens and the limited availability of mucosal adjuvants. He...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2023-01, Vol.11 (2), p.305
Main Authors: Yang, Jieru, Boer, Jennifer C, Khongkow, Mattaka, Phunpee, Sarunya, Khalil, Zeinab G, Bashiri, Sahra, Deceneux, Cyril, Goodchild, Georgia, Hussein, Waleed M, Capon, Robert J, Ruktanonchai, Uracha, Plebanski, Magdalena, Toth, Istvan, Skwarczynski, Mariusz
Format: Article
Language:English
Subjects:
adjuvant
Adjuvants
Antibodies
Antigens
Bacterial vaccines
cell-penetrating peptide
Chitosan
Clinical trials
Control
Cytokines
Dendritic cells
Design and construction
Dosage and administration
Formulations
Gram-positive bacteria
group A Streptococcus
Immune system
Immunization
Immunogenicity
Intranasal medication
intranasal vaccine
Liposomes
Methods
Mucosa
multilamellar liposome
oleoyl-quaternized chitosan
Peptides
Polymers
Proteins
Streptococcus
Streptococcus infections
Vaccine development
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intranasal vaccine administration can overcome the disadvantages of injectable vaccines and present greater efficiency for mass immunization. However, the development of intranasal vaccines is challenged by poor mucosal immunogenicity of antigens and the limited availability of mucosal adjuvants. Here, we examined a number of self-adjuvanting liposomal systems for intranasal delivery of lipopeptide vaccine against group A Streptococcus (GAS). Among them, two liposome formulations bearing lipidated cell-penetrating peptide KALA and a new lipidated chitosan derivative (oleoyl-quaternized chitosan, OTMC) stimulated high systemic antibody titers in outbred mice. The antibodies were fully functional and were able to kill GAS bacteria. Importantly, OTMC was far more effective at stimulating antibody production than the classical immune-stimulating trimethyl chitosan formulation. In a simple physical mixture, OTMC also enhanced the immune responses of the tested vaccine, without the need for a liposome delivery system. The adjuvanting capacity of OTMC was further confirmed by its ability to stimulate cytokine production by dendritic cells. Thus, we discovered a new immune stimulant with promising properties for mucosal vaccine development.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines11020305